Bioactive peptides present in milk proteins could potentially have beneficial effects on human health. Various camel milk protein hydrolysates were produced using different food-grade enzymes at various time of hydrolysis. In vitro inhibitory properties of novel bioactive peptides released from camel milk proteins against dipeptidyl peptidase-IV (DPP-IV), and pancreatic α-amylase (PA), were studied. Results revealed that upon hydrolysis by different enzymes, camel milk proteins displayed dramatic increase in inhibition of DPP-IV and only slight improvement in PA inhibition was noticed. Peptide sequencing revealed a total of 20 and 3 peptides for A9 and B9 respectively, obtained the score of 0.8 or more on peptide ranker and were categorized as potentially active peptides eligible to be DPP-IV inhibitory peptide. KDLWDDFKGL in A9 and MPSKPPLL in B9 were identified as most potent PA inhibitory peptide. The present study report for the first time PPA and PPL inhibitory and only second for DPP-IV inhibitory potential of protein hydrolysates from camel milk. Moreover, trypsin hydrolysed camel milk proteins released LLQLEAIR and LPVP, which had a DPP-IV half maximal inhibitory concentration (IC₅₀) of 83.6 ± 4.6 and 93.3 ± 3.6 µM (P > 0.05), respectively. DPP-IV inhibitory peptide sequences within camel milk protein hydrolysates differ from those found in a bovine milk protein hydrolysate. Camel milk proteins can provide novel DPP-IV inhibitory peptides, which may be used to regulate glycemia in humans.